Abstract: A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus+), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.

Abstract: The invention relates to the diagnosis of bladder cancer and more specifically to the detection in urine samples of bladder carcinomas of the transitional type. The detection method according to the present invention enables, through the utilization of a DNA chip designed for this purpose, to determine the grade of the detected tumors.

Abstract: The invention relates to the diagnosis of bladder cancer and more specifically to the detection in urine samples of bladder carcinomas of the transitional type. The detection method according to the present invention enables, through the utilization of a DNA chip designed for this purpose, to determine the grade of the detected tumors.

Abstract: The invention relates to the diagnosis of bladder cancer and more specifically to the detection in urine samples of bladder carcinomas of the transitional type. The detection method according to the present invention enables, through the utilization of a DNA chip designed for this purpose, to determine the grade of the detected tumors.

Abstract: The invention relates to the diagnosis of bladder cancer and more specifically to the detection in urine samples of bladder carcinomas of the transitional type. The detection method according to the present invention enables, through the utilization of a DNA chip designed for this purpose, to determine the grade of the detected tumors.

Abstract: The invention includes a prediction method for the screening or diagnosis or therapeutic management or prognosis of prostate cancer, including collecting individual input data and providing predictive information on the risk linked to a type of disease. The input data includes at least one variable or a combination of variables of the genetic type such as the identification of markers of genetic polymorphisms considered as being linked to the development of the disease. The invention also provides an individual prediction device for the screening or diagnosis or therapeutic management or prognosis of prostate cancer including first means for acquiring individual information data by a user, and at least a first software interface on which the said first means operate. The invention additionally includes a computer program product having the method and providing predictive information on risk linked to a disease.

Abstract: The invention relates to the diagnosis of bladder cancer and more specifically to the detection in urine samples of bladder carcinomas of the transitional type. The detection method according to the present invention enables, through the utilization of a DNA chip designed for this purpose, to determine the grade of the detected tumors.

Abstract: The invention relates to a method for in vitro evaluation of the aggressiveness of tumor cells by measuring the level of expression of all or part of a gene coding for semaphorin 3A in healthy epithelial cells and in epithelial tumor cells. The invention also relates to a method of inhibiting the invasive power of epithelial tumor cells, consisting in increasing the levels of semaphorin 3A levels present in and/or in the vicinity of said epithelial tumor cells.

Abstract: The invention relates to a method for producing a non-human A mammal with a prostatic tumor. The invention also relates to a prostatic tumor and an established cell line which can form a prostatic tumor in dogs after grafting has occurred. The invention further relates to specific monoclonal antibodies of prostatic tumoral cells and to the use thereof in diagnosis or therapy.